EGFR-targeting nanobodies have been isolated by phage display, also in competition with other specific ligands (i.e., EGF or cetuximab), leading to the identification of several excellent scaffolds that have been used to target EGFR-overexpressing cancers [208,209,210]. Here, EGFR is linked to cancer.